Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older and are being treated by a specialist for either Crohn's disease or plaque psoriasis.
- You have been treated with the original (reference) version of the medication Ustekinumab for at least 6 months before joining the study.
- Your condition has been stable for at least 3 months and is considered to be in remission (well-controlled) according to your doctor.
- Your specialist has already decided, as part of your normal care, to switch you to a biosimilar version of Ustekinumab made by a company called Celltrion.
- You have an email address and a mobile phone number.
- You are able to read and fill in questionnaires written in French.
- You are willing to take part in the study.
- You are covered by French Social Security (or are a beneficiary of someone who is).
Who may not be able to join:
- People who are under legal guardianship or whose freedom is otherwise restricted.
- Women who are pregnant or who are planning to become pregnant during the study.
- People who are already taking part in another clinical trial or study that does not allow them to join additional studies at the same time.
- People who have a medical reason why they cannot take the study medication (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33 1 71 25 27 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Maintenance of remission, 12 months after initiation of biosimilar treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.